Blog Layout

Tackling Treatment-Resistant Depression

Jun 28, 2020

Tackling Treatment-Resistant Depression

We dive into the nitty gritty of treatment-resistant depression and how we can defeat it.

Tackling Treatment-Resistant Depression

Services

Anace Said

Physician/Co-founder

6/28/2020


Depression isn’t just sadness

We’ve all felt sadness before, and it’s a normal, healthy part of life. We feel sad when we lose a loved one or when we don’t achieve our goals, but we eventually move on and heal. I want you to know that depression is decidedly not that; it’s a much deeper and persistent emotional pain that we can’t shake. According to the Mayo Clinic, it’s “a mood disorder that causes a persistent feeling of sadness and loss of interest,” and “it affects how you feel, think and behave and can lead to a variety of emotional and physical problems.” Depression might also cause motivation to fall for normal activities; some even feel that “life isn’t worth living,” a severe but frequent manifestation of the disease (1). In addition to feeling worthless, patients often see themselves as too feeble or lazy to pick themselves up. Throughout my years of practice, I’ve found one thing to hold true: depression is an invisible, dark vortex that can be as lethal as a heart attack. 

Depression is a disease, just like any other

Just like any other disease, we can take steps to manage depression, but we can’t just wish it away. This fact is essential to recognize because we can become depressed despite having no significant challenges in our lives, and I’ve seen people from all walks of life suffer. Even the wealthiest among us commit suicide, illustrating that the disease doesn’t care who you are or what you have. Depression is also unfortunately ubiquitous; 18.1% of the adult American population suffers from depression each year, and nearly 50% of people with depression also have an anxiety disorder (2). Besides therapy and support, the most common treatment for depression are SSRIs, a class of drugs that increases serotonin levels in the brain by blocking their reuptake by neurons (3). The most common SSRIs include citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline. These medications have proven to be very safe and effective, but they may not work for everyone.

Even if treatments fail, there’s hope

Typically, we consider a treatment ineffective after 4-8 weeks of trying. After this point, the depression becomes treatment-resistant, and we begin to explore other options. This occurrence is not uncommon; up to one-third of patients with depression do not respond to typically used antidepressants (4). One of these options is esketamine (Spravato®), a revolutionary new drug that the FDA approved in 2019. A double-blind, double-randomized, and placebo-controlled study in 2017 found that among 56 participants (average age 44.7 years old), there was a significant improvement in symptoms compared to the placebo. Perhaps even more interestingly, the study found that the positive effects of nasal esketamine remained despite tapering the dose down after weeks (5). It’s important to note that the patients in the study were people with a history of trying different medications without success.

How it works

Esketamine is an N-methyl D-aspartate (NMDA) receptor antagonist. That jargon basically says that esketamine attaches to the receptor that NMDA usually binds to, preventing NMDA from attaching to the receptor. Although the exact reason for esketamine’s efficacy isn’t known, one theory is that it promotes new connections within the brain in the neurons responsible for mood.

Our experiences with treatment

Since we began treating patients using nasal esketamine (Spravato®), we’ve had some incredible success stories. One of our patients had been suffering from depression for more than a decade despite trying a plethora of medication regimes. The patient constantly felt the classic symptoms of depression: self-loathing, guilt, and a general feeling of worthlessness. When we tried esketamine (Spravato®), the patient noticed a significant improvement in symptoms, remarking that they felt like themselves again after all these years. I love making impacts in people’s lives, and it amazes me that science has come such a long way to afford us such life-changing medications.

  1. https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007
  2. https://adaa.org/about-adaa/press-room/facts-statistics
  3. https://www.mayoclinic.org/diseases-conditions/depression/in-depth/ssris/art-20044825
  4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838571/
  5. ibid.
The Nitty Gritty Of Trigger Point Injections
28 Jun, 2020
Many of us suffer from chronic pain in various areas of our bodies. Often, the go-to solutions don’t work as well as we hope, and they can have damaging side effects. For example, acetaminophen can take a toll on the liver, while ibuprofen may damage the lining of the gut over time. Rest doesn’t always help, and, while physical therapy can be a great long term solution, sometimes we need things that are more immediate.
New Study on Bionic Pancreases
21 Jun, 2020
A new study in the New England Journal of Medicine finds that a bionic pancreas was more effective in controlling hemoglobin A1C levels compared to standard care.
Welcome to Our Website
21 Jun, 2020
Hello everybody! Welcome to our brand new website. We hope this website makes it easy for you to find the information you need and get in touch with us as easily as possible. Here’s a quick run through of all the features of the website (more coming soon!)
When You Unlock Your Potential
21 Jun, 2020
One of our patients was having trouble focusing, and as a college student, that meant her grades were taking a hit. Of course, not everyone who has less-than-desirable grades should be treated for ADHD, but she presented with all the right symptoms. As such, treatment for ADHD was appropriate for her.
New Medication Tirzepatide for Weight Loss
21 Jun, 2020
Tirzepatide is a ground-breaking new medication originally indicated for the treatment of diabetes. A new study in the NEJM shows its efficacy for treating weight loss. In the phase 3, double blind, randomized clinical trial, roughly 2500 adults were assigned in equal numbers to 3 doses of the drug and a placebo. The key points? Over the course of 72 weeks, they observed:
New Medicatoin Retatrutide for Weight Loss in Phase 2 Trials
21 Jun, 2020
So, we’ve heard about tirzepatide (read here), but there’s another drug in the process of research called retatrutide. The medication works similarly to tirzepatide, but it also acts on two other hormones that control blood sugar, per this Insider article.
Share by: